Efficacy of indole carbinol in patients with simple endometrial hyperplasia without atypia in perimenopause


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Objective. To assess whether indole carbinol can be used to treatperimenopausal patients with simple endometrial hyperplasia without atypia. Subjects and methods. A study group (Group 1) included 34 perimenopausal women with simple endometrial hyperplasia without atypia; a comparison group (Group 2) consisted of 34 patients without proliferative endometrial diseases. Group 1 (twenty patients) was treated with indole carbinol at a dose of 300 mg/day for 3 months. Pelvic ultrasonography and hysteroscopy with endometrial biopsy were performed and the urinary levels of 2-hydroxyestrone (2-OHE) and 16α-hydroxyestrone (16α-OHE) were measured by enzyme immunoassay using the Estramet 2/16 Elisa kit (USA) according to the standard procedure in the patients of both groups before treatment and in those of Group 1 after treatment. The results obtained were statistically processed using the Excel, Statistica 6.0, and SISA programs (http://home.clara.net/sisa/). Results. The histological study of endometrial aspiration after a 3-month indole carbinol treatment cycle showed the absence of endometrial hyperplasia in 100%. After indole carbinol treatment, there was a significant increase in the 2-OHE1/16αOHE1 ratio relative to its initial value. There was a statistically significant decrease in 16α-OHE1 levels from 35.58±14.84 ng/mg before treatment to 20.05±3.5 ng/mg after treatment (p = 0.0001). Conclusion. In perimenopausal women, the use of indole carbinol is accompanied by a decrease in the level of 16α-OHE1 metabolite and by an increase in the 2- OHE/16α- OHE1 ratio and can be an effective treatment for simple endometrial hyperplasia without atypia.

Texto integral

Acesso é fechado

Sobre autores

Natalya Artymuk

Kemerovo State Medical University, Ministry of Health of Russia

Email: artymuk@gmail.com
MD, PhD, Professor, the Head of the Department of Obstetrics and Gynecology named after Professor G.A. Ushakova

Ekaterina Kharenkova

S.V. Belyaev Kemerovo Regional Hospital

Email: Caty-20@rambler.ru
MD, PhD, Gynecological Department No. 2

Olga Tachkova

Kemerovo State Medical University, Ministry of Health of Russia

Email: ol.an.t@yandex.ru
MD, PhD, Associate Professor at the Department of Hospital Therapy and Clinical Pharmacology

Bibliografia

  1. Goldstein S.R., Lumsden M.A. Abnormal uterine bleeding in perimenopause. Climacteric. 2017; 20(5): 414-20. doi: 10.1080/13697137.2017.1358921.
  2. Sanderson P.A., Critchley H.O., Williams A.R., Arends M.J., Saunders P.T. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017; 23(2): 232-54. doi: 10.1093/humupd/dmw042.
  3. MacKintosh M.L., Derbyshire A.E., McVey R.J., Bolton J., Nickkho-Amiry M., Higgins C.L., Kamieniorz M., Pemberton P.W., Kirmani B.H., Ahmed B., Syed A.A., Ammori B.J., Renehan A.G., Kitchener H.C., Crosbie E.J. The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk. Int J. Cancer. 2019; 144(3): 641-50. doi: 10.1002/ijc.31913.
  4. Chandra V., Kim J.J., Benbrook D.M., Dwivedi A., Rai R. Therapeutic options for management of endometrial hyperplasia. J. Gynecol Oncol. 2016; 27(1): e8. doi: 10.3802/jgo.2016.27.e8
  5. Auclair M.H., Yong P.J., Salvador S., Thurston J., Colgan T.T.J., Sebastianelli A. Guideline No. 392-Classification and Management of Endometrial Hyperplasia. J. Obstet Gynaecol Can. 2019; 41(12): 1789-1800. doi: 10.1016/j.jogc.2019.03.025.
  6. Nieman K.M., Romero I.L., Van Houten B., Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013; 1831(10): 1533-41. doi: 10.1016/j.bbalip.2013.02.010.
  7. Sahoo S.S., Lombard J.M., Ius Y., O’Sullivan R., Wood L.G., Nahar P., Jaaback K. Tanwar PS. Adipose-Derived VEGF-mTOR Signaling Promotes Endometrial Hyperplasia and Cancer: Implications for Obese Women. Mol Cancer Res. 2018; 16(2): 309-21. doi: 10.1158/1541-7786.MCR-17-0466.
  8. Management of Endometrial Hyperplasia Green-top Guideline No. 67 RCOG/ BSGE Joint Guideline. February, 2016.
  9. Gerhauser C. Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. Top Curr Chem. 2013; 329: 73-132. doi: 10.1007/128_2012_360.
  10. Ашрафян Л.А., Бабаева Н.А., Антонова И.Б., Овчинникова О.А., Алешикова О.И., Моцкобили Т.А., Кузнецов И.Н. Уровень баланса эстрогенных метаболитов при раке молочной железы и пути его коррекции. Опухоли репродуктивной системы. 2015; 3: 22-9
  11. Adwas A.A., Elkhoely A.A., Kabel A.M., Abdel-Rahman M.N., Eissa A.A. Anti-cancer and cardioprotective effects of indol-3-carbinol in doxorubicin-treated mice. J Infect Chemother. 2016; 22(1): 36-43. doi: 10.1016/ j.jiac.2015.10.001
  12. Wang S.Q., Cheng L.S., Liu Y., Wang J.Y., Jiang W. Indole-3-earbinol (I3C) and its Major Derivatives: Their Pharmacokinetics and Important Roles in Hepatic Protection. Curr Drug Metab. 2016; 17(4): 401-9. doi: 10.2174/138920021766 6151210125105
  13. Perez-Chacon G., de Los Rios C., Zapata J.M. Indole-3-carbinol induces cMYC and IAP-family down modulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt’s lymphoma cell lines. Pharmacol Res. 2014; 89: 46-56. doi: 10.1016/j.phrs.2014.08.005.
  14. Xiao X., Meng Q., Xu J., Jiao Y., Rosen E.M., Fan S. EGFR-dependent impact of indol-3-carbinol on radiosensitivity of lung cancer cells. Zhongguo Fei Ai Za Zhi. 2012; 15(7): 391-8. doi: 10.3779/j.issn.1009-3419.2012.07.01.
  15. Kundu A, Khouri M.G., Aryana S., Firestone G.L. 1-Benzyl-indole-3-carbinol is a highly potent new small molecule inhibitor of Wnt/P-catenin signaling in melanoma cells that coordinately inhibits cell proliferation and disrupts expression of microphthalmia-associated transcription factor isoform-M. Carcinogenesis. 2017; 38(12): 1207-17. doi: 10.1093/carcin/bgx103.
  16. Quirit J.G., Lavrenov S.N., Poindexter K., Xu J., Kyauk C., Durkin K.A., Aronchik I., Tomasiak T., Solomatin Y.A., Preobrazhenskaya M.N., Firestone G.L. Indole-3-carbinol (I3C) analogues are potent small molecule inhibitors of NEDD4-1 ubiquitin ligase activity that disrupt proliferation of human melanoma cells. Biochem Pharmacol. 2017; 127: 13-27. doi: 10.1016/j.bcp.2016.12.007.
  17. Kundu A., Quirit J.G., Khouri M.G., Firestone G.L. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation. Mol Carcinog. 2017; 56(1): 49-61. doi: 10.1002/mc.22472.
  18. Tin A.S., Park A.H., Sundar S.N., Firestone G.L. Essential role of the cancer stem/progenitor cell marker nucleostemin for indole-3-carbinol anti-proliferative responsiveness in human breast cancer cells. BMC Biol. 2014; 12: 72. doi: 10.1186/s12915-014-0072-6.
  19. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W., Sherman Sh., Sluss P.M., de Villiers T.J., for the STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387-95. doi: 10.1097/gme.0b013e31824d8f40
  20. Chinni S.R., Sarkar F.H. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clinical Cancer Research. 2002; 8: 1228-36. PMID: 11948137
  21. Will A.J., Sanchack K.E. Endometrial Biopsy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020-2019 May 5. PMID: 31082179
  22. Ашрафян Л.А., Киселев В.И., Кузнецов И.Н., Муйжнек Е.Л., Герфанова Е.В., Вашакмадзе С.Л. Молекулярная онкобиология и перспективы эффективной терапии. Онкология. Журнал им. П.А.Герцена. 2016; 5(3): 80-7. https://doi.org/10.17116/ onkolog20165280-87
  23. Ашрафян Л.А., Киселев В.И. Скрининг и ранняя диагностика рака репродуктивных органов. М.: Молодая гвардия, 2016. 244 c.
  24. Савельева Г.М., Сухих Г.Т., Серов В.Н., Радзинский В.Е., Манухин И.Б., ред. Гинекология: национальное руководство. М.: ГЭОТАР-Медиа, 2017. 1008 с.
  25. Киселев В.И., Сметник В.П., Сутурина Л.В., Селиванов С.П., Рудакова Е.Б., Рахматуллина И.Р.; Андреева Е.Н., Фадеева Н.И., Хасанов Р.Ш., Кулагина Н.В., Рожкова Н.И., Артымук Н.В., Гависова А.А., Муйжнек Е.Л., Кузнецов И.Н., Друх В.М. Индолкарбинол (Индинол Форто) - метод мультитаргетной терапии при циклической мастодинии. Акушерство и гинекология. 2013; 7: 56-62.
  26. Сметник В.П., Гависова А.А., Билак Н.П., Друх В.М. Эффективность индолкарбинола при циклической мастодинии. Проблемы репродукции. 2013; 5: 49-53.
  27. Tsiskarishvili N.V., Nadareishvili L.N., Tsiskarishvili Ts.I. New possibilities for elimination of human papillomavirus from the organism. Georgian Med News. 2011; (192): 34-8. [n Russ.]. PMID: 21525537

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2020

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies